Lion TCR is a clinical-stage biotechnology company, focused on the development of T cell receptor (TCR)-T cell therapy against life-threatening viral infections and viral-related cancers pertinent in Asia.
In Asia, more than 20% of new cancer cases per year are attributable to chronic infections. In particular, a large majority of hepatocellular carcinomas are due to chronic infection with the hepatitis B virus (HBV) which is endemic in Asia.
At Lion TCR, over a decade’s worth of basic research, product engineering and development, and pre-clinical/clinical assessment have culminated in our leading product that harnesses the power of a patient’s own immune system to eliminate HBV-related hepatocellular carcinoma.
Together with our world-renowned scientific advisors, we continue to develop novel immunotherapies against viral infections and their related cancers afflicting the Asian population.